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Abstract
Patients with chronic kidney disease (CKD) have increased risk of fractures, yet the optimal
treatment is unknown. In secondary analyses of large randomized trials, bisphosphonates have
been shown to improve bone mineral density and reduce fractures. However, bisphosphonates are
currently not recommended in patients with advanced kidney disease due to concern about over-
suppressing bone remodeling, which may increase the risk of developing arterial calcification. In
the present study we used a naturally occurring rat model of CKD with secondary
hyperparathyroidism, the Cy/+ rat, and compared the efficacy of treatment with zoledronic acid,
calcium given in water to simulate a phosphate binder, and the combination of calcium and
zoledronic acid. Animals were treated beginning at 25 weeks of age (approximately 30% of
normal renal function) and followed for ten weeks. The results demonstrate that both zoledronic
acid and calcium improved bone volume by microCT and both equally suppressed mineral
apposition rate, bone formation rate, and mineralizing surface of trabecular bone. In contrast, only
calcium treatment with or without zoledronic acid improved cortical porosity and cortical
biomechanical properties (ultimate load and stiffness) and lowered parathyroid hormone (PTH).
However, only calcium treatment led to the adverse effects of increased arterial calcification and
fibroblast growth factor 23 (FGF23). These results suggest zoledronic acid may improve
trabecular bone volume in CKD in the presence of secondary hyperparathyroidism, but does not
benefit extraskeletal calcification or cortical biomechanical properties. Calcium effectively
reduces PTH and benefits both cortical and trabecular bone yet increases the degree of extra
skeletal calcification.
Introduction
Chronic kidney disease – mineral and bone disorder (CKD-MBD) is a disorder of abnormal
biochemistries, bone fragility and arterial calcification in patients with advanced CKD(1).
Patients with CKD have increased risk of bone fracture compared to the general
population(2). The increased fracture risk is due to a combination of abnormal bone quantity
and quality(3,4).
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The pathophysiology of bone loss associated with CKD-MBD is different than post-
menopausal osteoporosis suggesting that extrapolation of data from trials of treatments in
post-menopausal or corticosteroid-induced osteoporosis may not be appropriate. Secondary
analyses of randomized controlled trials of bisphosphonates in post-menopausal women
subsequently identified to have kidney disease demonstrated reduced fracture risk and
improved bone mineral density without adverse consequences(5-7). However, these patients
had neither advanced kidney disease nor elevated PTH levels. These differences provided
the rationale for global clinical practice guidelines to recommend against treating patients
with CKD stage 3b-5 with bisphosphonates without a bone biopsy(8). We have previously
used our slowly progressive animal model of CKD-MBD to test different doses of the
bisphosphonate zoledronic acid on bone mass, turnover, and biomechanical properties in
animals with hyperparathyroidism and moderate renal disease(9). In the present study, we
extend these findings to compare the skeletal (both cortical and cancellous) and vascular
effects of zoledronic acid with and without calcium in the setting of high and low PTH
levels in CKD animals with more advanced renal disease.
Materials and Methods
Animal model and experimental design
Male Cy/+ rats, Han:SPRD rats with autosomal dominant polycystic kidney disease, and
their non-affected (normal) littermates were used for this study. Male heterozygous rats (Cy/
+) develop characteristics of CKD (azotemia) around 10 weeks of age which progresses to
terminal uremia by about 40 weeks. This animal model spontaneously develops all three
manifestations of CKD-MBD: biochemical abnormalities, extra skeletal calcification, and
abnormal bone(10,11).
At 25 weeks of age, animals were assigned to treatment groups. In the CKD (Cy/+) animals,
this age represents approximately 30-40% of the kidney function of the normal littermates.
This was chosen to simulate late stage 3 CKD, a stage at which there is elevated PTH, yet
normal calcium and phosphorus levels, and a stage at which clinical practice guidelines do
not recommend treatment with bisphosphonates(8). The CKD treatment groups (n=10 per
group) were given 1) a single subcutaneous (SQ) dose of vehicle as control (CTL) and
normal deionized drinking water, 2) a single SQ dose of zoledronic acid (ZOL) (20 μg/kg
body weight) and normal deionized drinking water, 3) no injection but administered 3%
calcium gluconate (3% Ca) in the drinking water, or 4) Zoledronic acid plus 3% Ca in the
drinking water (Ca + ZOL). The calcium gluconate group was used to simulate calcium
administration as a phosphate binder. In addition, we studied age-matched normal (NL)
littermate animals (n = 10) to determine if treatments normalized bone manifestations or
extra skeletal calcification. All animals were fed a casein diet (Purina AIN-76A; 0.53% Ca
and 0.56% P) during the experiment which has been shown to produce a more consistent
kidney disease in this model(10). Two weeks prior to the end of the study, all animals were
given an intraperitoneal injection of calcein (1% concentration, 0.1mL/100g body weight); a
second injection was given 10 days later. At 35 weeks of age all animals were euthanized by
an overdose of sodium pentobarbital. All procedures were reviewed and approved by the
Indiana University School of Medicine Institutional Animal Care and Use Committee.
Tissues collection and analysis
At sacrifice at 35 weeks, blood and urine were collected by cardiac and bladder puncture,
respectively. The heart and aorta arch were excised and weighed. Left ventricular mass
index (LVMI) was determined by dividing total heart weight by body weight. To quantify
aorta and heart calcification, proximal segments of the ascending aorta and a segment of the
inferior apex of the left ventricle of the heart were snap frozen and the degree of
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calcification determined biochemically as previously described (12). Left tibiae were placed
in 10% neutral buffered formalin for 48 hours and then changed to 70% ethanol for imaging
followed by histological processing.
Serum and urine biochemical measurements
Blood plasma was analyzed for BUN, calcium, phosphorus, and creatinine using
colorimetric assays (Point Scientific, Canton, MI, USA, or Sigma kits). Intact PTH was
determined by ELISA (Alpco, Salem, NH, USA). FGF23 was assessed with a two-site assay
(Immunotopics, San Clemente, CA, USA). Urine was analyzed for creatinine, calcium, and
phosphorus using the colorimetric methods described above (11).
Computed tomography (CT)
Morphological parameters of the proximal tibia were assessed using high-resolution
microCT (Skyscan 1172). Bones were wrapped in parafilm to prevent drying during
scanning. Scans were obtained using an x-ray source, set at 60kV and 167 μA over an
angular range of 180 degrees (rotational steps of 0.70 degrees) with a 12-μm pixel size.
Projection images were reconstructed using standard Skyscan software (NRecon). A 1mm
region of interest of the proximal tibia (located ∼ 0.5 mm distal to the growth plate) was
analyzed by segmenting the trabecular bone from the cortical shell and calculating
trabecular bone volume per total volume (BV/TV) in accordance with recommended
guidelines (13). On the most distal slice of the 1 mm region of interest, the cortical shell was
manually isolated from the trabecular bone by tracing the periosteal and endocortical edges.
Porosity of the cortical shell was calculated as total bone area within the cortex divided by
total area of bone plus void space within the cortex.
Bone Histomorphometry
Tibiae were embedded in methylmethacrylate for sectioning as previously described (9,14).
The proximal tibial metaphysis was thin sectioned (4 μm) and mounted unstained using non-
fluorescent medium. Sections were analyzed using a microscope interfaced with a
semiautomatic analysis system (Bioquant OSTEO 7.20.10, Bioquant Image Analysis Co.).
Two of ten CKD vehicle-treated animals, and two of nine CKD calcium-treated animals did
not have double labels in the proximal tibia section region of interest. In these animals, tibia
midshafts were sectioned and also found to contain no double label. This suggests these
animals were not properly administered both labels (likely due to injection directly into
bladder) and thus these animals were excluded from the histological analysis, according to
previously published recommendations(15). For trabecular bone analyses, a region of
interest of approximately 8 mm2 within the secondary spongiosa (∼ 0.5 mm distal to the
growth plate) was defined, and then measures of single- and double-label perimeter (sL.Pm,
dL.Pm), total bone perimeter (B.Pm) and interlabel width (Ir.L.Wi) were conducted. From
these primary measurements, derived parameters were calculated as: mineralizing surface
(MS/BS = [1/2sL.Pm + dL.Pm]/B.Pm; %), mineral apposition rate (MAR =Ir.l.W/days
between labels; μm/day), and bone formation rate (BFR/BS = MAR × MS/BS × 3.65; μm3/
μm2/yr). All parameters were measured and calculated in accordance with ASBMR
recommended standards(16).
Bone Mechanics
Femora were tested via three-point bending using standard methods as previously described
for the rat.(9). Femora were thawed to room temperature, hydrated in 0.9% saline, and
placed on the bottom support of a servo-hydraulic test system (Test Resources). All bones
were loaded to failure in an anterior-posterior direction using a displacement rate of 2 mm/
min with force vs. displacement data collected at 10 Hz. Structural mechanical properties,
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ultimate load, stiffness, and energy to failure were determined from the load-deformation
curves using standard definitions.
Statistics
All analyses were run using SigmaStat software. The five groups were compared using a
one-way ANOVA with Fisher's post-hoc analyses for within group comparisons.
Correlations were examined by the Pearson product-moment algorithm. A priori α-levels
were set at 0.05. Data are presented as means and standard errors.
Results
Biochemical outcomes
At 35 weeks, there was no difference in the plasma BUN in the CKD animal treatment
groups, but values for all CKD animals were higher than normal animals as expected (CKD
BUN 59.6 ± 1.5 vs. NL BUN 19.9 ± 0.63 mg/dl). The total body weight was not different
between any of the 5 groups. There were overall differences in the other blood results
(Figure 1 A-D): In the CKD rats, treatment with calcium, both alone and in combination
with zoledronic acid, led to an increase in plasma calcium (p < 0.001) and FGF23 (p <
0.005) levels and a decrease in PTH (p < 0.001) and phosphorus (p < 0.05) levels compared
to CKD-CTL. In contrast, treatment with zoledronic acid alone had no significant effect on
these biochemical measures. The effect of the combination of zoledronic acid with calcium
was not different than calcium alone for any of these plasma biochemistry results. The
plasma calcium level was negatively correlated with PTH (r = -0.53, p < 0.001) and
positively correlated with FGF23 (r = 0.44, p < 0.002). The plasma phosphorus level was
more strongly related to the PTH (r = 0.79, p < 0.001) than FGF23 (r = 0.33, p < 0.003). The
urine calcium/creatinine ratio was significantly increased in both calcium treatment groups
(Vehicle = 0.27 ± 0.09; Zol = 0.27 ± 0.12; Ca = 0.70 ± 0.22; Zol + Ca = 0.50 ± 0.20 mg/mg,
p < 0.0001). The urine phosphorus/creatinine ratio was decreased in both calcium treatment
groups (Vehicle = 1.33 ± 0.56; Zol = 1.75 ± 0.44; Ca = 1.08 ± 0.49; Ca + Zol = 0.79 ± 0.35
mg/mg, overall p = 0.002). The albumin/creatinine ratio was not different among the groups.
Cardiovascular outcomes
At 35 weeks, the CKD animals had increased left ventricular mass index (LVMI) compared
to normal animals (p<0.001) that was unaffected by treatments (CKD + CTL = 3.8 ± 0.19,
CKD + Ca = 3.9 ± 1.2, CKD + ZOL = 4.0 ± 0.4, CKD + Ca + ZOL = 4.0 ± 0.4, Nl +Vehicle
3.2 ± 0.06, overall p = 0.035). However, treatment with calcium increased aortic arch
calcium content, and this adverse effect was mitigated by zoledronic acid (Figure 2). The
aorta arch calcium content was significantly (all p < 0.01) correlated with LVMI (r = 0.48),
BUN (r = 0.47), calcium (r = 0.43), and FGF23 (r = 0.51) but not phosphorus or PTH. In
contrast to our previous studies in this model (12), there was no difference in the heart
calcification between any of the groups.
Bone outcomes
By microCT, there was no difference in the trabecular bone volume between CKD and NL
animals. ZOL, calcium, and calcium + ZOL treatment significantly increased percent bone
volume (p<0.0001) in CKD rats but there was no difference among these three treatment
groups (Figure 3A). The bone volume was strongly correlated with trabecular number (r =
0.77, p < 0.001).The trabecular bone volume was positively correlated with the calcium (r =
0.53) and FGF23 (r = 0.42), negatively correlated with PTH (r = -0.47; all p < 0.01), but not
correlated with phosphorus. Cortical porosity was increased in CKD animals compared to
normal animals, with significant reduction in animals treated with calcium and calcium plus
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ZOL; the ZOL treatment showed a non-significant reduction (p = 0.13;Figure 3B).
Corresponding three-dimensional reconstruction of the microCT images are shown in Figure
3C. The magnitude of cortical porosity was strongly associated with phosphorus (r = 0.80)
and PTH (r = 0.70, both p < 0.001), but not associated with FGF23, calcium or bone
volume.
Dynamic bone histomorphometry demonstrated that the mineralization apposition rate
(MAR) was increased in the CKD animals compared to normal, and decreased by all
treatments in the CKD animals to levels similar to that observed in NL animals (Figure 4A).
Similar results were observed for mineralizing surface (MS/BS; Figure 4B) and BFR (Figure
4C). PTH and phosphorus were positively associated with all three histomorphometric
indices with the strongest relationship with MAR (r = 0.61 for PTH and r = 0.42 for
phosphorus, both p < 0.01). The calcium level was negatively correlated only with BFR (r =
-0.35, p = 0.03) and MS/BS (r =-0.53, p < 0.001).
Ultimate load and stiffness of the femoral diaphysis were both significantly lower in
untreated CKD animals compared to NL (Table 1, Figure 5). CKD animals treated with
ZOL had properties similar to untreated CKD (and lower than NL-VEH), while those treated
with calcium, or the combination of ZOL and calcium had mechanical properties
significantly higher than CKD and similar to NL.
Relationship of bone to cardiovascular outcomes
The aortic arch calcification was correlated with trabecular bone volume (r= 0.43, p = 0.005)
and cortical porosity (r = 0.34, p = 0.03), but not with any of the three histormorphometry
measures.
Discussion
Multiple studies have documented increased fractures in patients with CKD due to a
combination of abnormal bone volume and bone quality(17,18). While secondary analyses
support the use of bisphosphonates in post-menopausal women with moderate to advanced
kidney disease, these studies did not enroll individuals with elevated PTH levels (5,7).
Clinical practice guidelines recommend lowering PTH as a primary treatment approach in
CKD(8). There is no evidence that bisphosphonates directly reduce PTH; however their
potent bone resorption inhibition could effectively offset the osteoclast-medicated effects of
high PTH. We have previously shown efficacy of zoledronic acid in improving trabecular
bone volume in animals with earlier stages of CKD and mild hyperparathyroidism(9). In the
present study we tested the hypothesis that zoledronic acid would be efficacious in animals
with more advanced CKD, severe hyperparathyroidism, and even when combined with oral
calcium supplementation. The latter has been shown to induce low bone turnover in patients
on dialysis(19). Our results demonstrate that individually, zoledronic acid and calcium each
improved trabecular bone volume and reduced bone formation rate and the mineralizing
surface to a similar magnitude, but only the calcium treatment improved cortical porosity
and cortical biomechanical properties. In addition, only the calcium treatment induced
hypercalcemia and increased arterial calcification, although hypercalcemia was not a
prerequisite for aortic calcification. These results demonstrate that lowering PTH is more
effective at improving cortical bone porosity and biomechanical integrity, however, doing so
with calcium may adversely impact arterial calcification risk. The elevations in plasma
calcium levels may have a played a role in inducing aorta calcification, and it is possible that
lower doses of calcium would not results in this adverse effect. In our previous study in this
animal model we demonstrated that the administration of calcium at similar doses to the
current study led to aorta calcification. This occurred even if the calcium was given together
with a calcimimetic that resulting in normal plasma calcium levels resulting in increased
Moe et al. Page 5
J Bone Miner Res. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
calcium load but normal calcium levels(12). These results would imply that it is the calcium
load, not the level itself that contributes to calcification. However, dose finding studies
would be required to fully assess the importance of elevated calcium levels versus calcium
load or decreased bone formation.
The concern over the use of bisphosphonates in CKD has been the potential induction of low
turnover bone disease(8). In the present study, zoledronic acid did not suppress BFR any
more than calcium alone. In humans, zoledronic acid has been shown to improve bone
mineral density and reduce bone fractures in both primary and secondary prevention trials in
patients with post-menopausal osteoporosis(20-22). In contrast, in post-menopausal
osteoporosis the efficacy of calcium alone on fracture prevention is minimal to uncertain(23)
and its adverse effects have recently come under scrutiny(24). We cannot definitively
determine if the efficacy of calcium on bone in the present study was due to calcium itself,
or suppression of PTH, but based on the strong correlation of PTH, but not calcium, with
cortical porosity it is most likely PTH-mediated. Interestingly, the effects of zoledronic acid
on improving trabecular bone volume in the present study was less than compared to our
previous study(9) when the drug was given at an earlier time point with less severe
hyperparathyroidism and over a 5 week duration. One possible explanation is that the severe
hyperparathyroidism induced such a profound increase in bone resorption that the zoledronic
acid bound to bone was actually resorbed out of bone with the ‘first pass’ effect of the
osteoclasts, leaving little drug bound for continued effect as the drug was only dosed one
time. This dosing schedule was used to mimic the dosing to osteoporosis patients, where a
single dose is given once per year – about two remodeling cycles in humans. Ten weeks in a
rat is also equivalent to about two remodeling cycles. If true that a single dose was
inefficient to control osteoclasts over this duration, this could be overcome by using a less
potent bisphosphonate, such as alendronate or risedronate, normally administered on a more
regular basis (daily/weekly). Current clinical practice guidelines recommend dose reduction
of bisphosphonates in the setting of CKD(8). Our data suggests that the pharmacokinetics
could be altered in the setting of significant secondary hyperparathyroidism requiring
increased dosing frequency although perhaps a lower dose could still be given. Thus, further
studies are needed to evaluate pharmacokinetics of bisphosphonates in CKD, and further
studies should determine if the efficacy and adverse effects of zoledronic acid are different
when given to CKD animals and humans with and without hyperparathyroidism. It should
also be emphasized that changes in bone volume may not reflect an improvement in
biomechanical properties/strength. Zoledronic acid did not improve cortical measures of
strength, but similar measures to test strength of trabecular bone are not available.
In our CKD animals, the hyperparathyroidism produced profound changes in cortical bone
porosity and biomechanical properties that were corrected with the administration of
calcium. Cortical bone is more adversely affected than trabecular bone in
hyperparathyroidism(25,26). However, traditional assessment of renal osteodystrophy by
bone biopsy in CKD patients has been with trabecular bone. Our results suggest that the
apparent disconnect between PTH and bone turnover assessed by histology in cross
sectional studies(27) may be partly due to the use of trabecular bone. Supporting this is that
in patients with CKD, the distal radius X-ray absorptiometry (DXA), which is nearly
entirely cortical bone, is more predictive of fractures than other sites(28). These data, and
our results in the present study, support current clinical practice guidelines that emphasize
treating hyperparathyroidism as first line agent in patients with CKD stages 3-5D(8).
However, in a recent study of nearly 4000 hemodialysis patients, the largest fracture
assessment study to date in CKD, there was no effect of the calcimimetic cinacalcet on
fractures despite improved PTH(29). However, this study only evaluated clinical (reported)
fractures and thus may have underestimated true fracture prevalence and efficacy of
lowering PTH. Thus more studies specifically designed to compare the treatment of
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hyperparathyroidism versus anti-resorptive agents on fracture prevention in CKD are
required.
Previous studies have demonstrated that bisphosphonates reduce arterial calcification in
CKD animal models. Tamura found that etidronate decreased arterial calcification in 5/6th
nephrectomy rats also given calcitriol(30). Price found similar efficacy in the adenine model
of CKD treated with alendronate or ibandronate(31). Lomashevilli found that pamidronate
reduced arterial calcification in 5/6th nephrectomy animals treated with high phosphate diet,
but also found suppression of bone turnover and concluded the drug may be efficacious but
not safe, although there was no comparison of the degree of bone turnover to normal
animals (32). Bisphosphonates work by suppression of remodeling and therefore induce
lower bone formation rates are expected. In our previous study, the level of BFR
suppression was no different in CKD animals treated with zoledronic acid compared to
normal animals treated with zoledronic acid(9). In the current study, the turnover was
equally suppressed with zoledronic acid compared to calcium given in the drinking water (to
act as a phosphate binder, a treatment used worldwide).
A major concern about inducing suppressed bone turnover is the association of such
suppression with arterial calcification in patients with CKD and in dialysis
patients(19,33,34). This has been hypothesized to be due to the inability of bone to take up
excess calcium in the setting of low bone formation rates(35), predisposing to extra skeletal
deposition. In the present study we found that despite similar suppression of BFR with
zoledronic acid and calcium, only the calcium induced arterial calcification and suppression
of PTH and zoledronic acid appears to ameliorate this effect but had no efficacy by itself.
Thus, positive calcium balance which occurs in CKD(36) may be a critical factor involved
in the development of arterial calcification. The calcium treatment also increased FGF23 as
has been previously noted in animals(37). In other studies of human and animal arteries,
FGF23 appeared to be protective against arterial calcification, but only when klotho was
present(38). We have previously shown in our animal model that klotho expression in the
kidney is markedly decrease as early as 20 weeks(11) and thus, assuming similar
suppression in arteries, this potential positive effect of FGF23 may have been negated with
advanced kidney disease. The mechanism by which calcium stimulates FGF23 is likely
direct on the osteocytes, as calcium altered FGF23 secretion in rats who had undergone a
parathyroidectomy and then were infused with calcium or given a high calcium diet (37).
This increase in FGF23 may have adverse cardiac consequences in rodents(33,39), and
higher FGF23 levels have been found to predict progression of LVH in patients with CKD
3-4(39). In the current study, we did not observe differences in the LVH in animals with the
various treatments, but the duration of therapy was relatively short.
In humans with ESRD, there are only small studies examining the role of bisphosphonates in
the prevention of arterial calcification. In small cohort or observational studies from Japan,
etidronate reduced arterial calcification(40-42). In contrast, in a randomized controlled trial
of 50 patients, Toussaint et al found that alendronate had no effect on arterial
calcification(43). These differences may be explained by the increased mineral dissolution
properties of etridronate compared to alendronate and other nitrogen containing
bisphosphonates, although a number of other explanations such as dosing and disease stage
are also plausible.
In summary, we found similar efficacy of calcium and a single dose of zoledronic acid on
improving trabecular bone volume in animals with advanced CKD and severe
hyperparathyroidism. However, only the calcium treatment improved cortical porosity and
lowered PTH. Unfortunately, calcium also induced arterial calcification whereas zoledronic
acid did not despite similar suppression of bone remodeling. These results suggest that
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suppression of bone remodeling with bisphosphonates may not have the same adverse
consequences as suppression of bone remodeling with calcium. It is important to caution on
the extrapolation of changes in bone remodeling or bone volume in animal studies to human
disease. However, the data supports the conduct of a study in CKD patients directly testing
whether suppression of PTH with non-calcium containing agents (e.g. calcimimetics) are
more effective than anti-resorptive agents for fracture prevention.
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Figure 1. Biochemical changes in response to therapies
CKD animals were treated beginning at 25 weeks of age with control vehicle (CTL),
calcium in drinking water daily for 10 weeks (Ca), zoledronic acid 20 ug/kg given
subcutaneously once at 25 weeks (ZOL), or the combination of Ca + ZOL. The results were
compared to normal animals (NL) treated with vehicle. Blood was drawn at 35 weeks of
age. The results demonstrate that treatment with calcium, with or without zoledronic acid,
led to increased calcium levels (A), increased fibroblast growth factor 23 (B), decreased
parathyroid hormone levels to those in normal animals (C), and decreased phosphorus levels
(D). *= different than NL; + = different than CKD-CTL; # = different than CKD + ZOL; all
p < 0.05. Graphs are mean ± SEM, n = 8 to 10 per group.
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Figure 2. Aorta arch calcification in response to therapies
CKD animals were treated beginning at 25 weeks of age with control vehicle (CTL),
calcium in drinking water daily for 10 weeks (Ca), zoledronic acid 20 ug/kg given
subcutaneously once at 25 weeks (ZOL), or the combination of Ca + ZOL. The results were
compared to normal animals (NL) treated with vehicle. The aorta calcium content was
determined biochemically. The results demonstrated that CKD animals given any treatment
had increased aorta calcification compared to NL animals, and that the treatment with
calcium increased calcification further among the CKD animals. The co-administration of
calcium with zoledronic acid led to a reduction of the calcium induced arterial calcification
compared to calcium alone. *= different than NL; + = different than CKD-CTL; $ =
different than CKD + Ca; all p < 0.05. Graphs are mean ± SEM, n = 8 to 10 per group.
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Figure 3. Trabecular bone volume and cortical porosity in response to therapies
CKD animals were treated beginning at 25 weeks of age with control vehicle (CTL),
calcium in drinking water daily for 10 weeks (Ca), zoledronic acid 20 ug/kg given
subcutaneously once at 25 weeks (ZOL), or the combination of Ca + ZOL. The results were
Moe et al. Page 16
J Bone Miner Res. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
compared to normal animals (NL) treated with vehicle. At sacrifice at 35 weeks, the tibiae
were assessed by microCT for trabecular bone volume (A) and cortical porosity (B). The
results demonstrate that there was no difference in trabecular bone volume between CKD
and NL animals treated with vehicle. However, all of the treatments led to higher bone
volume in the CKD animals compared to CKD-vehicle. In contrast, the cortical porosity was
increased in vehicle treated CKD animals compared to NL animals. Treatment with calcium,
or calcium plus zoledronic acid, but not ZOL alone, reduced cortical porosity to NL levels.
The 3D reconstructions (C) provide visualization of these trabecular and cortical effects
across groups.*= different than NL; + = different than CKD-CTL; all p < 0.05. Graphs are
mean ± SEM, n = 7 to 10 per group.
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Figure 4. Bone histomorphometry in response to therapies
CKD animals were treated beginning at 25 weeks of age with control vehicle (CTL),
calcium in drinking water daily for 10 weeks (Ca), zoledronic acid 20 ug/kg given
subcutaneously once at 25 weeks (ZOL), or the combination of Ca + ZOL. The results were
compared to normal animals (NL) treated with vehicle. At sacrifice at 35 weeks, the tibiae
were processed for bone histomorphometry. The results for mineral apposition rate (MAR;
A), mineralizing surface as a percentage of bone surface (MS/BS; B), and bone formation
rate (BFR; C). The results demonstrate that there was higher MAR, BFR, and MS/BS in the
CKD animals treated with vehicle compared to NL animals. Treatment with calcium
orzoledronic acid reduced all parameters to levels similar in the NL animals with additive
reduction in the calcium plus zoledronic acid group. The *= different than NL; + = different
than CKD-CTL; # = different than CKD + ZOL; all p < 0.05. Graphs are mean ± SEM, n =
7 to 10 per group.
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Figure 5. Bone biomechanics in response to therapies
CKD animals were treated beginning at 25 weeks of age with control vehicle (CTL),
calcium in drinking water daily for 10 weeks (Ca), zoledronic acid 20 ug/kg given
subcutaneously once at 25 weeks (ZOL), or the combination of Ca + ZOL. The results were
compared to normal animals (NL) treated with vehicle. At sacrifice at 35 weeks, the femora
were tested via three-point bending. The results demonstrate that the CKD animals had
reduced ultimate load (fracture predisposition) than normal animals and this was improved
by calcium treatment with or without zoledronic acid The *= different than NL; + =
different than CKD-CTL; # = different than CKD + ZOL; all p < 0.05. Graphs are mean ±
SEM, n = 7 to 10 per group.
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